Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are re